Skip to Main Content
Table 4—

Cardiovascular outcomes and infections associated with PTD in kidney transplant recipients

Outcome and investigatorsDuration of follow-up (years)Number of patients with outcome/total number of patients (%)
RR (95% CI)
PTD presentPTD absent
Cardiovascular complications     
 von Kiparski et al. (21) 10 9/32 (28) 3/32 (9.4) 3 (0.98–9.6) 
Myocardial infarction     
 Miles et al. (17) 8.5 3/40 (7.5) 3/38 (7.9) 0.95 (0.2–3.9) 
Stroke     
 Miles et al. (17) 8.5 2/40 (5) 1/38 (2.6) 1.9 (0.4–14.2) 
Severe infections requiring hospitalization     
 Boudreaux et al. (8,9) 6/7 (86) 40/98 (40.8) 1.9 (1–2.6) 
 von Kiparski et al. (21) 10 12/32 (37.5) 6/32 (18.8) 2 (0.9–4.6) 
Cytomegalovirus infections     
 Vesco et al. (10,11) 14/33 (42.4) 7/33 (21.2) 2 (0.96–4.3) 
Fatal sepsis     
 Lanerolle et al. (16) 3–9 3/34 (8.8) 1/131 (0.8) 11.6 (1.7–79) 
 Miles et al. (17) 8.5 5/40 (12.5) 1/38 (2.6) 4.8 (0.8–30) 
Outcome and investigatorsDuration of follow-up (years)Number of patients with outcome/total number of patients (%)
RR (95% CI)
PTD presentPTD absent
Cardiovascular complications     
 von Kiparski et al. (21) 10 9/32 (28) 3/32 (9.4) 3 (0.98–9.6) 
Myocardial infarction     
 Miles et al. (17) 8.5 3/40 (7.5) 3/38 (7.9) 0.95 (0.2–3.9) 
Stroke     
 Miles et al. (17) 8.5 2/40 (5) 1/38 (2.6) 1.9 (0.4–14.2) 
Severe infections requiring hospitalization     
 Boudreaux et al. (8,9) 6/7 (86) 40/98 (40.8) 1.9 (1–2.6) 
 von Kiparski et al. (21) 10 12/32 (37.5) 6/32 (18.8) 2 (0.9–4.6) 
Cytomegalovirus infections     
 Vesco et al. (10,11) 14/33 (42.4) 7/33 (21.2) 2 (0.96–4.3) 
Fatal sepsis     
 Lanerolle et al. (16) 3–9 3/34 (8.8) 1/131 (0.8) 11.6 (1.7–79) 
 Miles et al. (17) 8.5 5/40 (12.5) 1/38 (2.6) 4.8 (0.8–30) 
Close Modal

or Create an Account

Close Modal
Close Modal